Journal of the American College of Cardiology | 9 Feb 2018
R Asleh, A Briasoulis, WK Kremers, R Adigun, BA Boilson, NL Pereira, BS Edwards, AL Clavell, JA Schirger, RJ Rodeheffer, RP Frantz, LD Joyce, S Maltais, JM Stulak, RC Daly, J Tilford, WG Choi, A Lerman and SS Kushwaha
Small studies have reported superiority of sirolimus (SRL) over calcineurin inhibitor (CNI) in mitigating cardiac allograft vasculopathy (CAV) after heart transplantation (HT). However, data on the long-term effect on CAV progression and clinical outcomes are lacking.
* Data courtesy of Altmetric.com